Navrogen Inc. is a biopharmaceutical company focused on the targeted treatment of cancer. Navrogen is currently working on enhancing the immune system to fight cancer by removing the effect of factors produced or induced by tumor cells which inhibit the cancer-fighting humoral immune system.
Total Funding: $6,200,000
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2017
Nov 2021
- Navrogen Published Preclinical Data
Sep 2021
- Navrogen Enters Into CRADA With USAMRIID
Aug 2021
- Navro Biotherapeutics Annogen Inc. and Tavotekunce Strategic Collaboration
Jul 2021
- Navrogen Signs Commercial Evaluation License Agreement
